Tuesday, Affymax Inc. (AFFY) closed its underwritten public offering of 4.7 million shares of its common stock, which includes the full exercise of the underwriter's overallotment option of 616,438 shares. The net proceeds to the company after deducting underwriting discounts and commissions and estimated offering expenses are approximately $80.0 million.
Cowen and Company, LLC and Lazard Capital Markets LLC were joint book-runners on the offering and RBC Capital Markets Corp. and Robert W. Baird & Co. Inc. were co-managers for the offering.
Affymax Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.